BIOA
Price
$7.71
Change
-$0.30 (-3.75%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
276.26M
Intraday BUY SELL Signals
SBFM
Price
$1.67
Change
-$0.10 (-5.65%)
Updated
Nov 13 closing price
Capitalization
8.24M
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIOA vs SBFM

Header iconBIOA vs SBFM Comparison
Open Charts BIOA vs SBFMBanner chart's image
BioAge Labs
Price$7.71
Change-$0.30 (-3.75%)
Volume$4.45K
Capitalization276.26M
Sunshine Biopharma
Price$1.67
Change-$0.10 (-5.65%)
Volume$104.77K
Capitalization8.24M
BIOA vs SBFM Comparison Chart in %
BIOA
Daily Signal:
Gain/Loss:
SBFM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BIOA vs. SBFM commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a Hold and SBFM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (BIOA: $8.01 vs. SBFM: $1.77)
Brand notoriety: BIOA and SBFM are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOA: 64% vs. SBFM: 4%
Market capitalization -- BIOA: $276.26M vs. SBFM: $8.24M
BIOA [@Pharmaceuticals: Generic] is valued at $276.26M. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $8.24M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOA’s FA Score shows that 1 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • BIOA’s FA Score: 1 green, 4 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, BIOA is a better buy in the long-term than SBFM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOA’s TA Score shows that 3 TA indicator(s) are bullish while SBFM’s TA Score has 4 bullish TA indicator(s).

  • BIOA’s TA Score: 3 bullish, 5 bearish.
  • SBFM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SBFM is a better buy in the short-term than BIOA.

Price Growth

BIOA (@Pharmaceuticals: Generic) experienced а +6.80% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

SBFM is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOA($276M) has a higher market cap than SBFM($8.24M). BIOA has higher P/E ratio than SBFM: BIOA (0.57) vs SBFM (0.00). BIOA YTD gains are higher at: 38.342 vs. SBFM (-41.000). SBFM has higher annual earnings (EBITDA): -6.19M vs. BIOA (-77.68M). BIOA has more cash in the bank: 297M vs. SBFM (10.3M). SBFM has less debt than BIOA: SBFM (929K) vs BIOA (8.75M). SBFM has higher revenues than BIOA: SBFM (36.3M) vs BIOA (3.86M).
BIOASBFMBIOA / SBFM
Capitalization276M8.24M3,349%
EBITDA-77.68M-6.19M1,254%
Gain YTD38.342-41.000-94%
P/E Ratio0.570.0056,219%
Revenue3.86M36.3M11%
Total Cash297M10.3M2,883%
Total Debt8.75M929K941%
FUNDAMENTALS RATINGS
BIOA vs SBFM: Fundamental Ratings
BIOA
SBFM
OUTLOOK RATING
1..100
8785
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
43
Fair valued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
3646
P/E GROWTH RATING
1..100
3281
SEASONALITY SCORE
1..100
5026

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBFM's Valuation (43) in the null industry is in the same range as BIOA (47) in the Chemicals Specialty industry. This means that SBFM’s stock grew similarly to BIOA’s over the last 12 months.

BIOA's Profit vs Risk Rating (93) in the Chemicals Specialty industry is in the same range as SBFM (100) in the null industry. This means that BIOA’s stock grew similarly to SBFM’s over the last 12 months.

SBFM's SMR Rating (95) in the null industry is in the same range as BIOA (99) in the Chemicals Specialty industry. This means that SBFM’s stock grew similarly to BIOA’s over the last 12 months.

BIOA's Price Growth Rating (36) in the Chemicals Specialty industry is in the same range as SBFM (46) in the null industry. This means that BIOA’s stock grew similarly to SBFM’s over the last 12 months.

BIOA's P/E Growth Rating (32) in the Chemicals Specialty industry is somewhat better than the same rating for SBFM (81) in the null industry. This means that BIOA’s stock grew somewhat faster than SBFM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOASBFM
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
BIOA
Daily Signal:
Gain/Loss:
SBFM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTNOY14.63N/A
N/A
DNO ASA
BYMOF92.36N/A
N/A
Bayerische Motoren Werke AG
KTEL0.28N/A
-0.38%
KonaTel, Inc.
LITOF0.50-0.02
-3.01%
Frontier Lithium
AKBTY2.79-0.11
-3.79%
Akbank Turk Anonim Sirketi

BIOA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOA
1D Price
Change %
BIOA100%
+2.30%
UPC - BIOA
42%
Loosely correlated
+2.22%
SBFM - BIOA
20%
Poorly correlated
+1.14%
AMRX - BIOA
20%
Poorly correlated
-0.42%
AKBA - BIOA
9%
Poorly correlated
+2.21%
SUPN - BIOA
7%
Poorly correlated
-3.23%
More

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and OGI have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and OGI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
+1.14%
OGI - SBFM
25%
Poorly correlated
-1.83%
ELAN - SBFM
23%
Poorly correlated
-3.54%
NBIX - SBFM
23%
Poorly correlated
-0.30%
AQST - SBFM
23%
Poorly correlated
-1.93%
CGC - SBFM
22%
Poorly correlated
-0.83%
More